Doximity IPO Presentation Deck
THE DIGITAL PLATFORM
FOR DOCTORS
Leading Network Blue Chip Clients
80%+ 20/20 21%
of all U.S.
Physicians¹
Top Hospitals
and Health Systems
Subscription
Revenue Growth5
Top Pharmaceutical
Manufacturers³
Growth and Profit
380K 117% 44%
Net Revenue
Retention Rate4
Adj. EBITDA
Margin
Telehealth Unique
Active Providers²
doximity
5:47
The Lancet Respiratory Medicine
16
A
Atypical Presentation of COVID-19 in a 34 Year-
Old Man
22min read-CME
The pandemic of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) challenges
15 Comments
Natalia Birgisson, MD
Resident Physician
0 61
I was struck by the multiple possible etiologies
explaining his course, and what a reminder more
34-Reply
10
Add a comment
Anupam Jena, MD
your colleague was published 1d
Incremental Health Care Burden of
Treatment-Resistant Depression Among
Commercial, Medicaid, and Medicare...
Psychiatric services (Washington, DC.)
1. As of 3/31/23.
2. For fiscal quarter ending 3/31/23.
3. Top 20 Pharmaceutical Manufacturers based on data from FiercePharma, Top 20 hospitals based on U.S. News & World Report's Best Hospitals 2021-2022 Rankings.
4. For the trailing twelve month (TTM) period ending 3/31/23. Refer to appendix for the definition of Net Revenue Retention.
5. For the trailing twelve month (TTM) period ending 3/31/23. This excludes the impact of the AMION acquisition, which closed on April 1, 2022, including subscription revenue generated from the AMION on-call scheduling and messaging
application, and the impact of such acquisition was immaterial to the periods presented. This also excludes subscription revenue generated from Dialer Pro subscriptions for individuals and small practices and other non-recurring items.
6. For the trailing twelve month (TTM) period ending 3/31/23. Refer to appendix for the definition and non-GAAP reconciliation of Adjusted EBITDA and Adjusted EBITDA Margin.
Proprietary
3View entire presentation